Cooper Companies Posts Smaller Than Expected Q3 Profits, Guidance Lags Estimates

  • Cooper Companies Inc's COO Q3 FY22 revenues increased 10% Y/Y to $843.4 million, up 18% in constant currency and 9% organically, beating the consensus of $832.68 million.
  • The CooperVision (CVI) segment revenue increased 2% to $566.3 million, and CooperSurgical (CSI) revenue up 35% to $277.1 million.
  • Adjusted EPS of $3.19 was down 6% Y/Y, missing the consensus of $3.24.
  • The adjusted gross margin was 66%, down from 68% last year. Adjusted operating margin compressed to 23% from 27% in last year's first quarter.
  • Cash provided by operations of $263.9 million, offset by capital expenditures of $46.6 million, resulted in a free cash flow of $217.3 million.
  • Related: What This Analyst Expects From Cooper Companies Q3 Earnings.
  • Guidance: Cooper Companies expects FY22 sales of $3.29-$3.31 billion versus the previous guidance of $3.28-$3.31 billion and the consensus of $3.29 billion.
  • The outlook includes CVI segment revenue of $2.24 - $2.25 billion and CSI segment sales of $1.06 - $1.06 billion.
  • For FY22, the company expects adjusted EPS of $12.72 - $12.87, versus the consensus of $13.14 and prior guidance of $13.09 - $13.29.
  • For Q4 FY22, the company expects sales of $830 - $850 million, compared to the consensus of $841.43 million.
  • It forecasts an adjusted EPS of $3.05 - $3.20 below the consensus of $3.42.
  • Price Action: COO shares traded 1.09% higher at $290.59 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!